Dong-A Pharmaceutical announce on December 21th that the company has concluded an agreement
with Mitsubishi Tanabe Pharma Corporation (President &CEO: Michihiro Tsuchiya) under which Dong-A shall
be granted an exclusive rights to develop, manufacture, and market TALION Eye Drops (bepotastine besilate*),
an allergic conjunctivitis treatment in Korea.



Dong-A Pharmaceutical has marketed it as TALION Tablets (the 2nd generation antihistamine) since 2004,
under the licensing agreement with the Mitsubishi Tanabe Pharma. TALION Eye Drops has the same
ingredients with TALION Tablets and developed by ISTA Pharmaceuticals, Inc., a partner of Mitsubishi Tanabe
Pharma in the US. It was approved in the US for use in treatment of allergic conjunctivitis in September 2009,
and is marketed under the brand name of BEPREVE in the US. BEPREVE has been clinically proven to produce
rapid and sustained relief of ocular itching.



Market size of allergic conjunctivitis in Korea is about 23billion Korean won in 2009, and the market is growing
17% annually. Because of the prevalent yellow dust from China, allergic conjunctivitis patients are growing fast
not only in spring but also in fall and winter as well.



Dong-A Pharmaceutical plans to make its efforts to develop an eye-drop formulation of TALION, and aims to
launch it in 2012. With this new line-up, Dong-A will bolster its franchise of both TALION and its ophthalmologic
field, and the company expects to grow as a global pharmaceutical company in the prescription drugs market
with the balanced portfolio of original and licensed-in product.



* Bepotastine Besilate: Bepotastine Besilate was co-developed by Mitsubishi Tanabe Pharma and Ube
Industries, Ltd. who discovered, and then it has marketed in Japan by Mitsubishi Tanabe Pharma for treatment
of allergic disorder under the brand name of TALION Tablets since 2000.